Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated:  2/7/2013
Clinical Research Facility
mi
from
Cleveland, OH
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated: 2/7/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated:  2/7/2013
Clinical Research Facility
mi
from
Portland, OR
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated: 2/7/2013
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated:  2/7/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated: 2/7/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated:  2/7/2013
Clinical Research Facility
mi
from
Sioux Falls, SD
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated: 2/7/2013
Clinical Research Facility
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated:  2/7/2013
Clinical Research Facility
mi
from
Dallas, TX
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated: 2/7/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated:  2/7/2013
Clinical Research Facility
mi
from
Norfolk, VA
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated: 2/7/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated:  2/7/2013
Clinical Research Facility
mi
from
Seattle, WA
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status: Enrolling
Updated: 2/7/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light
Status: Enrolling
Updated:  2/18/2013
St. Mary's Hospital - Mayo Clinic
mi
from
Rochester, MN
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light
Status: Enrolling
Updated: 2/18/2013
St. Mary's Hospital - Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light
Status: Enrolling
Updated:  2/18/2013
Ohio State University
mi
from
Columbus, OH
Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light
Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light
Status: Enrolling
Updated: 2/18/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Bioequivalence of Ethylenediamine Dihydrochloride Study
Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations
Status: Enrolling
Updated:  2/22/2013
Dermatology Specialists PSC
mi
from
Louisville, KY
Bioequivalence of Ethylenediamine Dihydrochloride Study
Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations
Status: Enrolling
Updated: 2/22/2013
Dermatology Specialists PSC
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
Status: Enrolling
Updated:  3/6/2013
Clinical Research Facility
mi
from
Dallas, TX
Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
Status: Enrolling
Updated: 3/6/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Birmingham, AL
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Bakersfield, CA
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Encino, CA
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Sacramento, CA
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Colorado Springs, CO
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Dunedin, FL
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Dunedin, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Jacksonville, FL
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Miami, FL
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Atlanta, GA
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Macon, GA
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Newnan, GA
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Newnan, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Champaign, IL
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Champaign, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Boston, MA
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Clinton Township, MI
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Clinton Township, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Fort Gratiot, MI
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Grand Blanc, MI
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Troy, MI
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Troy, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Fridley, MN
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Fridley, MN
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Verona, NJ
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Verona, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Bronx, NY
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Winston-Salem, NC
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Cleveland, OH
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Gahanna, OH
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Gahanna, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
Hershey, PA
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/14/2013
Clinical Research Facility
mi
from
San Antonio, TX
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-313 - PIONEER I A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/14/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
Status: Enrolling
Updated:  3/20/2013
NY Laser and Skin Care
mi
from
New York, NY
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
Status: Enrolling
Updated: 3/20/2013
NY Laser and Skin Care
mi
from
New York, NY
Click here to add this to my saved trials
An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa.
A Prospective Multi-Center Blinded, Randomized, Controlled Clinical Trial Comparing the Efficacy of Provodine Topical Body Wash Versus 10% Benzoyl Peroxide Topical Body Wash for the Treatment of Hidradenitis Suppurativa
Status: Enrolling
Updated:  3/21/2013
Henry Ford Medical Center Department of Dermatology
mi
from
Detroit, MI
An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa.
A Prospective Multi-Center Blinded, Randomized, Controlled Clinical Trial Comparing the Efficacy of Provodine Topical Body Wash Versus 10% Benzoyl Peroxide Topical Body Wash for the Treatment of Hidradenitis Suppurativa
Status: Enrolling
Updated: 3/21/2013
Henry Ford Medical Center Department of Dermatology
mi
from
Detroit, MI
Click here to add this to my saved trials
Collagen Injections for the Treatment of Acne Scars and Wrinkles
Pilot Study of Autologous Fibroblast Injection for Acne Scars, Forehead Lines, Lip Lines, Horizontal Neck Lines, and Static Crow's Feet
Status: Enrolling
Updated:  4/12/2013
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Collagen Injections for the Treatment of Acne Scars and Wrinkles
Pilot Study of Autologous Fibroblast Injection for Acne Scars, Forehead Lines, Lip Lines, Horizontal Neck Lines, and Static Crow's Feet
Status: Enrolling
Updated: 4/12/2013
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
An Investigator-Initiated Study to Assess the Degree of Irritation After a Second Cycle of Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
Status: Enrolling
Updated:  4/17/2013
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
An Investigator-Initiated Study to Assess the Degree of Irritation After a Second Cycle of Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
Status: Enrolling
Updated: 4/17/2013
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris
Status: Enrolling
Updated:  4/26/2013
Northwest Clinical Trials, Inc.
mi
from
Boise City, ID
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris
Status: Enrolling
Updated: 4/26/2013
Northwest Clinical Trials, Inc.
mi
from
Boise City, ID
Click here to add this to my saved trials
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris
Status: Enrolling
Updated:  4/26/2013
Shideler Clinical Research Center
mi
from
Carmel, IN
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris
Status: Enrolling
Updated: 4/26/2013
Shideler Clinical Research Center
mi
from
Carmel, IN
Click here to add this to my saved trials
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris
Status: Enrolling
Updated:  4/26/2013
Michigan Center for Research Corp
mi
from
Clinton Township, MI
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris
Status: Enrolling
Updated: 4/26/2013
Michigan Center for Research Corp
mi
from
Clinton Township, MI
Click here to add this to my saved trials
Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers
An Open-label Safety and Tolerability Study of LTS 0.3% With Ref Light Applied to the Backs of Healthy Volunteers
Status: Enrolling
Updated:  5/9/2013
TKL Research Inc (Research Clinics Division)
mi
from
Paramus, NJ
Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers
An Open-label Safety and Tolerability Study of LTS 0.3% With Ref Light Applied to the Backs of Healthy Volunteers
Status: Enrolling
Updated: 5/9/2013
TKL Research Inc (Research Clinics Division)
mi
from
Paramus, NJ
Click here to add this to my saved trials
Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions
A Comparison of Ingenol Mebutate and Cryotherapy for Treatment of Actinic Keratoses.
Status: Enrolling
Updated:  5/23/2013
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions
A Comparison of Ingenol Mebutate and Cryotherapy for Treatment of Actinic Keratoses.
Status: Enrolling
Updated: 5/23/2013
Northwestern University, Feinberg School of Medicine, Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
Seborrheic Dermatitis of the Scalp in Populations Practicing Less Frequent Hair Washing: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
Status: Enrolling
Updated:  6/1/2013
St. Louis University Department of Dermatology
mi
from
St. Louis, MO
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
Seborrheic Dermatitis of the Scalp in Populations Practicing Less Frequent Hair Washing: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
Status: Enrolling
Updated: 6/1/2013
St. Louis University Department of Dermatology
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) and Both Active Treatments to a Placebo in the Treatment of Acne Vulgaris.
Status: Enrolling
Updated:  6/10/2013
Akesis Investigational Site California
mi
from
Santa Ana, CA
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) and Both Active Treatments to a Placebo in the Treatment of Acne Vulgaris.
Status: Enrolling
Updated: 6/10/2013
Akesis Investigational Site California
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) and Both Active Treatments to a Placebo in the Treatment of Acne Vulgaris.
Status: Enrolling
Updated:  6/10/2013
Akesis Investigational Site Florida
mi
from
Brandon, FL
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) and Both Active Treatments to a Placebo in the Treatment of Acne Vulgaris.
Status: Enrolling
Updated: 6/10/2013
Akesis Investigational Site Florida
mi
from
Brandon, FL
Click here to add this to my saved trials
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) and Both Active Treatments to a Placebo in the Treatment of Acne Vulgaris.
Status: Enrolling
Updated:  6/10/2013
Akesis Investigational Site North Carolina
mi
from
Raleigh, NC
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) and Both Active Treatments to a Placebo in the Treatment of Acne Vulgaris.
Status: Enrolling
Updated: 6/10/2013
Akesis Investigational Site North Carolina
mi
from
Raleigh, NC
Click here to add this to my saved trials